The objective of FAST III is to determine the safety and effectiveness of an angiography-based vessel-Fractional Flow Reserve guided strategy versus an invasive FFR guided strategy to guide coronary revascularization in patients with intermediate coronary artery stenosis.

This randomized controlled, open-label, multicenter, international, non-inferiority, strategy trial aims to enroll a total of 2228 patients, in 7 European countries and approximately 35 hospitals. The FAST III trial is performed in accordance with the Declaration of Helsinki, Good Clinical Practice (GCP), ISO 14155:2020, EC requirements and country specific regulations.

The Principal Investigator is Dr. Joost Daemen (Erasmus Medical Center, Rotterdam, The Netherlands).

The European Cardiovascular Research Institute (ECRI) is the Sponsor of the FAST III trial. ECRI is being supported by scientific grants from Pie Medical Imaging (Maastricht, The Netherlands) and Siemens Healthineers AG (Erlangen, Germany).

The FAST III trial is registered at NCT04931771.